Legend Biotech Corp (LEGN)
Legend Biotech Corporation is a biopharmaceutical company whose ordinary shares are represented on NASDAQ through an American depositary receipt. Through its subsidiaries, the company develops, manufactures, and commercializes cell therapies for oncology and other therapeutic areas in the United States, China, and Europe. Its lead candidate is cilta-cel, or ciltacabtagene autoleucel, a CAR-T therapy being developed for multiple myeloma. Legend Biotech also has a pipeline of earlier-stage autologous CAR-T programs in several cancer types, including acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, small cell lung, and non-small cell lung cancers. In addition, it is advancing allogeneic gamma delta CAR-T and CAR-NK candidates targeting BCMA for multiple myeloma in investigator-initiated Phase 1 studies in China. The company maintains collaboration and license agreements with Janssen Biotech and Novartis Pharma AG. Founded in 2014, Legend Biotech is headquartered in Somerset, New Jersey.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LEGN
|
$24.37
|
30.7% Upside
|
Undervalued
|
$48.48
|
160.1% Upside
|
Bargain
|
Good
|
0.0%
|
November 17, 2026
|
2.9x
|
2.8x
|
3.612 B
|
2.904 B
|
7.2%
|
46.8%
|
3.7
|
133.1%
|
